Compare Manchester United PLC (MANU) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Organon & Co. Common Stock — how do they compare? Manchester United PLC trades at $20.68 (market cap $3.64B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Manchester United PLC and Organon & Co. Common Stock are close in size by market cap, and Manchester United PLC pays the higher dividend (1.26%). Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and Organon & Co. Common Stock for 0 Days on average.
| MANU | OGN | |
|---|---|---|
Market Cap | $3.64B | $3.62B |
Volume | 324,608 | 2,892,999 |
Sector | Media | Health |
52-Week High | $24.19 | $13.81 |
52-Week Low | $15.20 | $5.70 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $4.46B | $11.04B |
Dividend Yield | 1.26% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $20.59, down 1.15% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported fiscal 2026 revenue of $678 million with improved EBITDA of $216.4 million despite net losses, while analyst sentiment remains divided with 40% buy ratings. Recent news highlights the stock trading at a significant discount to Forbes' $7.2 billion franchise valuation estimate.
Investment outlook balances franchise value upside against persistent profitability challenges. Key opportunities include Champions League return and cost controls, while risks center on sustained losses, high debt, and competitive Premier League dynamics. The stock offers speculative appeal for franchise value believers but requires profitability improvement for sustained gains.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
